Healthcare provider profile · identity verified

Michael Daniel Angulo, MD

Family Practice · MAYAGUEZ, PR · NPI 1417541293

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	245	78
Amlodipine Besylate	Amlodipine Besylate	201	70
Losartan Potassium	Losartan Potassium	142	43
Lisinopril	Lisinopril	138	45
Levothyroxine Sodium	Levothyroxine Sodium	131	35
Gabapentin	Gabapentin	117	39
Tamsulosin Hcl	Tamsulosin Hcl	114	38
Glipizide	Glipizide	112	35
Meloxicam	Meloxicam	112	66
Rosuvastatin Calcium	Rosuvastatin Calcium	112	38
Metformin Hcl Er	Metformin Hcl	106	33
Metformin Hcl	Metformin Hcl	100	29
Jardiance	Empagliflozin	93	26
Pantoprazole Sodium	Pantoprazole Sodium	82	36
Trazodone Hcl	Trazodone Hcl	80	35
Omeprazole	Omeprazole	78	28
Albuterol Sulfate Hfa	Albuterol Sulfate	69	30
Alendronate Sodium	Alendronate Sodium	68	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	59	19
Metoprolol Succinate	Metoprolol Succinate	57	19
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	55	suppressed
Simvastatin	Simvastatin	51	15
Tramadol Hcl	Tramadol Hcl	51	16
Carvedilol	Carvedilol	47	18
Hydrochlorothiazide	Hydrochlorothiazide	46	16
Furosemide	Furosemide	44	13
Metoprolol Tartrate	Metoprolol Tartrate	41	15
Allopurinol	Allopurinol	40	11
Wixela Inhub	Fluticasone Propion/Salmeterol	40	11
Mirtazapine	Mirtazapine	37	19
Pradaxa	Dabigatran Etexilate Mesylate	37	13
Duloxetine Hcl	Duloxetine Hcl	34	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	34	suppressed
Methylprednisolone	Methylprednisolone	34	29
Sertraline Hcl	Sertraline Hcl	34	16
Atenolol	Atenolol	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	33	19
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	32	suppressed
Potassium Chloride	Potassium Chloride	30	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	29	suppressed
Montelukast Sodium	Montelukast Sodium	29	11
Lovastatin	Lovastatin	28	suppressed
Prednisone	Prednisone	27	23
Ozempic	Semaglutide	26	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Alprazolam	Alprazolam	23	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Pravastatin Sodium	Pravastatin Sodium	23	suppressed
Fenofibrate	Fenofibrate	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	20
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Ibuprofen	Ibuprofen	17	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	17	17
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Finasteride	Finasteride	14	suppressed
Veo Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	14	suppressed
Alvesco	Ciclesonide	13	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	13	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Methylphenidate Er	Methylphenidate Hcl	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Trospium Chloride	Trospium Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error